CA3189243A1 - Compositions et methodes de soulagement d'affections et de troubles neurologiques - Google Patents

Compositions et methodes de soulagement d'affections et de troubles neurologiques

Info

Publication number
CA3189243A1
CA3189243A1 CA3189243A CA3189243A CA3189243A1 CA 3189243 A1 CA3189243 A1 CA 3189243A1 CA 3189243 A CA3189243 A CA 3189243A CA 3189243 A CA3189243 A CA 3189243A CA 3189243 A1 CA3189243 A1 CA 3189243A1
Authority
CA
Canada
Prior art keywords
agent
pabra
less
dose
blocker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3189243A
Other languages
English (en)
Inventor
Anthony P. FORD
Gabriel VARGAS
Wei Chen
Renee S. MARTIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curasen Therapeutics Inc
Original Assignee
Curasen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curasen Therapeutics Inc filed Critical Curasen Therapeutics Inc
Publication of CA3189243A1 publication Critical patent/CA3189243A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/501—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the head, e.g. neuroimaging or craniography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon divers aspects et modes de réalisation, l'invention concerne des compositions et des méthodes permettant d'identifier des patients nécessitant une amélioration de la cognition et/ou de traiter une maladie neurodégénérative affectant un patient, et de traiter un tel patient. Plus spécifiquement, l'invention concerne, dans certains modes de réalisation, l'administration d'un agoniste de ?-AR (tel qu'un agent-?) et d'un ?-bloquant à action périphérique (PABRA) à un patient en ayant besoin.
CA3189243A 2020-09-01 2021-08-31 Compositions et methodes de soulagement d'affections et de troubles neurologiques Pending CA3189243A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063073353P 2020-09-01 2020-09-01
US63/073,353 2020-09-01
US202163212077P 2021-06-17 2021-06-17
US63/212,077 2021-06-17
PCT/US2021/048540 WO2022051305A1 (fr) 2020-09-01 2021-08-31 Compositions et méthodes de soulagement d'affections et de troubles neurologiques

Publications (1)

Publication Number Publication Date
CA3189243A1 true CA3189243A1 (fr) 2022-03-10

Family

ID=80491939

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3189243A Pending CA3189243A1 (fr) 2020-09-01 2021-08-31 Compositions et methodes de soulagement d'affections et de troubles neurologiques

Country Status (8)

Country Link
US (1) US20230263749A1 (fr)
EP (1) EP4208159A4 (fr)
JP (1) JP2023541379A (fr)
KR (1) KR20230107211A (fr)
AU (1) AU2021337583A1 (fr)
CA (1) CA3189243A1 (fr)
MX (1) MX2023002350A (fr)
WO (1) WO2022051305A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240162965A1 (en) 2021-03-03 2024-05-16 Lenovo (Singapore) Pte. Ltd. Beam failure detection using multiple sets of reference signals
WO2024137506A1 (fr) * 2022-12-21 2024-06-27 Curasen Therapeutics, Inc. Compositions et méthodes de soulagement de maladies et de troubles neurologiques

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952101A (en) * 1975-04-14 1976-04-20 Smithkline Corporation α-Amino methyl-5-hydroxy-2-pyridinemethanols
NZ226991A (en) * 1987-11-27 1992-03-26 Merck & Co Inc Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
CA2423792A1 (fr) * 2000-10-20 2002-04-25 Pfizer Products Inc. Ethanolamines alpha-aryle et utilisation de ces dernieres en tant qu'agonistes du recepteur adrenergique beta-3
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US9320724B2 (en) * 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
WO2018195473A1 (fr) * 2017-04-20 2018-10-25 The Brigham And Women's Hospital, Inc. Combinaisons comprenant des agonistes du récepteur bêta-adrénergique pour le traitement de la maladie de parkinson et de troubles du mouvement
AU2019287771A1 (en) * 2018-06-14 2021-01-28 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
US20210251559A1 (en) * 2018-06-14 2021-08-19 Curasen Therapeutics, Inc. Methods for diagnosing, monitoring and treating neurological diseases and disorders
KR20210143775A (ko) * 2019-03-27 2021-11-29 큐라센 테라퓨틱스, 인코포레이티드 베타 아드레날린성 작용제 및 이의 사용 방법
WO2021081292A1 (fr) * 2019-10-25 2021-04-29 Curasen Therapeutics, Inc. PROCÉDÉS DE TRAITEMENT DE TROUBLES NEUROLOGIQUES AVEC DES AGONISTES α1A-AR PARTIELS
JP2023507408A (ja) * 2019-12-18 2023-02-22 キュラセン セラピューティクス インコーポレイテッド 神経系疾患および障害を改善するための方法
EP4161496A4 (fr) * 2020-06-04 2024-08-21 Curasen Therapeutics Inc Formes et compositions d'un agoniste bêta-adrénergique

Also Published As

Publication number Publication date
AU2021337583A1 (en) 2023-05-04
WO2022051305A1 (fr) 2022-03-10
KR20230107211A (ko) 2023-07-14
AU2021337583A9 (en) 2024-06-27
EP4208159A4 (fr) 2024-09-25
US20230263749A1 (en) 2023-08-24
EP4208159A1 (fr) 2023-07-12
JP2023541379A (ja) 2023-10-02
MX2023002350A (es) 2023-04-26

Similar Documents

Publication Publication Date Title
US11607395B2 (en) Methods for improving neurological diseases and disorders
US7408079B2 (en) Imaging agents and methods of imaging NAALADase or PSMA
CN116617420A (zh) 靶向成纤维细胞活化蛋白α的化合物、药物组合物及用途
CA3100697A1 (fr) Procedes de diagnostic, de surveillance et de traitement de maladies et de troubles neurologiques
CA3100848A1 (fr) Procedes d'attenuation de maladies et de troubles neurologiques
CA3189243A1 (fr) Compositions et methodes de soulagement d'affections et de troubles neurologiques
CN109475594A (zh) 用于成像ido1酶的放射性配体
US10442767B2 (en) Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
US20230414588A1 (en) Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)
US20230157974A1 (en) Compositions and methods for improving neurological diseases and disorders
CA2911307C (fr) Utilisation de derives fluores de 4-aminopyridine en therapeutique et en imagerie medicale
CN116801875A (zh) 用于改善神经疾病和病症的组合物和方法
US20210251923A1 (en) Methods for improving neurological diseases and disorders
WO2024137506A1 (fr) Compositions et méthodes de soulagement de maladies et de troubles neurologiques
US20230357154A1 (en) Butyrylcholinesterase compounds and use in diseases of the nervous system
WO2024137478A1 (fr) Méthpdes de traitement de divers états pathologiques et indications avec des agonistes et des antagonistes
WO2023250332A1 (fr) Compositions et méthodes impliquant des composés isolés
WO2023250334A1 (fr) Compositions et méthodes impliquant des composés isolés
US9610369B2 (en) Compound suitable for detection of vesicular acetylcholine transporter
KR20170138437A (ko) 신경질환 치료용 푸마레이트를 정맥투여하는 방법 및 조성물